China A-share innovative drug stocks surge as Shanghai Composite rises 0.55%
On September 20, Chinese A-share markets rose, with the Shanghai Composite up 0.55% to 3933.37. Innovative drug, CRO, and biotech stocks led gains. The PBOC conducted 165 billion yuan in reverse repos. Vice Premier He Lifeng held trade consultations with US officials in New York. A pilot program for electronic customs clearance of imported drugs launched at Beijing ports.
IllustrationEditorial responsibility
- No named human review is recorded for this page.
- Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page reads the event directly, while its address stays stable when the title changes.
- Summary awaiting refresh
Summary awaiting refresh
Cross-source coverage
Reporting timeline
China A-Share Drug Stocks Surge; Shanghai Composite Rises 0.55% at Midday
China's A-share markets rose across the board at midday on September 20, with the Shanghai Composite up 0.55% to 3,933.37 points, the Shenzhen Component up 0.57%, and the ChiNext up 0.93%. The PBOC conducted a 165 billion yuan 7-day reverse repo at 1.40%. In policy news, China's Vice Premier He Lifeng met with US Treasury Secretary Bessent and Trade Representative Greer in New York for economic consultations, discussing trade and AI issues. The NMPA and General Administration of Customs launched a pilot for electronic customs clearance of imported drugs at Beijing ports. Sector-wise, recombinant proteins, CRO, biotech, chemical pharma, innovative drugs, and vitamins led gains, while precious metals and white goods lagged. Analysts provided stock-specific commentary: Tianfeng Securities noted Chengdu Biotech's HAILO platform and RIPTAC projects; Southwest Securities highlighted Huiyu Pharma's 13 innovative drug pipeline including HY-0007; Pacific Securities cited Hongbo Medical's growth from patent expirations; and Southwest Securities noted CanSino's accelerated overseas clinical progress.
China A-Share Innovation Drug Stocks Surge; Shanghai Composite Rises 0.55% at Midday
Chinese A-share markets rose across the board at midday on September 20, with the Shanghai Composite Index up 0.55% to 3,933.37, the Shenzhen Component Index up 0.57% to 13,718.23, and the ChiNext Index up 0.93% to 3,403.97. The central bank conducted a 165 billion yuan 7-day reverse repo operation at a rate of 1.40%. In policy news, China's Vice Premier He Lifeng held economic and trade consultations with U.S. Treasury Secretary Bessent and Trade Representative Greer in New York, discussing bilateral trade, investment, and AI issues. Separately, the National Medical Products Administration and the General Administration of Customs launched a pilot program for electronic customs clearance of imported drugs at Beijing ports. Sector-wise, recombinant proteins, CRO, biopharmaceuticals, chemical drugs, innovative drugs, and vitamins led gains, while precious metals and white goods lagged. Analysts from Tianfeng Securities noted that Chengdu Lead's HAILO platform is improving, supporting multiple RIPTAC projects. Southwest Securities reported that Huiyu Pharmaceutical has 13 innovative drug projects in R&D, with its HY-0007 dual antibody fusion protein in Phase I/II trials for advanced solid tumors. Pacific Securities stated that Hongbo Medical's commercial production is accelerating after the patent extension for ticagrelor ended in December 2024. Southwest Securities also said CanSino's overseas clinical trials are accelerating, potentially unlocking mid-to-long-term pipeline value.
Read sourceChina A-Share Innovation Drug Stocks Surge; Shanghai Composite Up 0.55% at Midday
China's A-share markets rose at midday on September 20, with the Shanghai Composite Index up 0.55% to 3933.37, the Shenzhen Component up 0.57%, and the ChiNext up 0.93%. The People's Bank of China conducted 165 billion yuan in 7-day reverse repos at a 1.40% rate. In diplomatic news, Chinese Vice Premier He Lifeng held trade consultations with US Treasury Secretary Bessent and Trade Representative Greer in New York, discussing bilateral trade, investment, and AI issues. The National Medical Products Administration and the General Administration of Customs launched a pilot program for electronic customs clearance of imported drugs at Beijing ports, effective immediately. Sector-wise, innovation drugs, CRO, biotech, and chemicals led gains, while precious metals and white goods lagged. Analysts provided forecasts: Tianfeng Securities noted Chengdu XianDai's HAILO platform and RIPTAC pipeline progress; Southwest Securities highlighted Huiyu Pharma's 13 innovative drug projects and its HY-0007 bispecific fusion protein in Phase I/II trials; Pacific Securities predicted rapid growth for Hongbo Medical's commercial production after the patent expiry of ticagrelor; and Southwest Securities said CanSino's overseas clinical acceleration could unlock mid-to-long-term pipeline value.
Read sourceShow 4 older updatesHide older updates
China A-Share Innovation Drug Stocks Surge; Shanghai Composite Up 0.55% at Midday
A-share indices rose at midday on September 20, with the Shanghai Composite up 0.55% to 3933.37, the Shenzhen Component up 0.57% to 13718.23, and the ChiNext up 0.93% to 3403.97. The PBOC conducted 165 billion yuan in 7-day reverse repos at 1.40%. In diplomatic news, Chinese Vice Premier He Lifeng met with US Treasury Secretary Bessent and Trade Representative Greer in New York for economic and trade consultations, including a dialogue on AI. The National Medical Products Administration and the General Administration of Customs launched a pilot for electronic customs clearance of imported drugs at Beijing ports, effective immediately. Sector-wise, recombinant protein, CRO, biological products, chemical pharmaceuticals, innovation drugs, and vitamins led gains, while precious metals and white goods lagged. Analysts provided forecasts: Tianfeng Securities noted Chengdu Biotech's HAILO platform and RIPTAC pipeline progress; Southwest Securities highlighted Huiyu Pharmaceutical's 13 innovative drug projects including HY-0007; Pacific Securities predicted rapid growth for Hongbo Medical's commercial production after the patent expiry of ticagrelor; and Southwest Securities said CanSino's overseas clinical trials are accelerating, potentially unlocking mid-to-long-term pipeline value.
Read sourceChina A-Share Innovative Drug Stocks Surge; Shanghai Composite Up 0.55% at Midday
Chinese A-share markets rose at midday on September 20, with the Shanghai Composite Index up 0.55% to 3933.37, the Shenzhen Component up 0.57% to 13718.23, and the ChiNext up 0.93% to 3403.97. The PBOC conducted 165 billion yuan in 7-day reverse repos at 1.40%. In diplomatic news, Chinese Vice Premier He Lifeng met with US Treasury Secretary Bessent and Trade Representative Greer in New York for economic and trade consultations, including a dialogue on AI. The National Medical Products Administration and the General Administration of Customs announced a pilot program for electronic customs clearance of imported drugs at Beijing ports, effective immediately. Sector-wise, recombinant protein, CRO, biotech, chemical pharma, innovative drugs, and vitamins led gains, while precious metals and white goods lagged. Analysts from Tianfeng, Southwest, and Pacific Securities provided forecasts on specific biotech firms: Tianfeng noted Chengdu First's HAILO platform and RIPTAC pipeline progress; Southwest highlighted Huiyu Pharma's HY-0007 dual antibody fusion protein in Phase I/II trials; Pacific pointed to Hongbo Medical's commercial production ramp after patent expiry; and Southwest noted CanSino's overseas clinical acceleration.
Read sourceChina A-Share Innovative Drug Stocks Surge; Shanghai Composite Up 0.55% at Midday
China's A-share markets rose across the board at midday on September 20, with the Shanghai Composite Index up 0.55% to 3933.37, the Shenzhen Component up 0.57% to 13718.23, and the ChiNext up 0.93% to 3403.97. The PBOC conducted 165 billion yuan in 7-day reverse repos at a 1.40% rate. In diplomatic news, Chinese Vice Premier He Lifeng met with US Treasury Secretary Bessent and Trade Representative Greer in New York for economic and trade consultations, including a dialogue on artificial intelligence. The National Medical Products Administration and the General Administration of Customs launched a pilot program for electronic customs clearance of imported drugs at Beijing ports. Sector-wise, recombinant proteins, CRO, biopharmaceuticals, chemical drugs, innovative drugs, and vitamins led gains, while precious metals and white goods lagged. Brokerage reports highlighted specific companies: Tianfeng Securities noted Chengdu Biostar's HAILO platform and RIPTAC pipeline; Southwest Securities highlighted Huiyu Pharmaceutical's HY-0007 dual-antibody fusion protein in Phase I trials; Pacific Securities cited Hongbo Medical's commercial production ramp after patent expiry; and Southwest Securities noted CanSino's accelerating overseas clinical trials.
Read sourceChina A-Share Innovative Drug Stocks Surge; Shanghai Composite Rises 0.55% at Midday
China's A-share markets rose at midday on September 20, with the Shanghai Composite up 0.55% to 3933.37, the Shenzhen Component up 0.57%, and the ChiNext up 0.93%. The central bank conducted 165 billion yuan in 7-day reverse repos at 1.40%. In diplomatic news, Chinese Vice Premier He Lifeng held trade consultations with US Treasury Secretary Bessent and Trade Representative Greer in New York, focusing on bilateral trade and investment. The National Medical Products Administration and General Administration of Customs announced a pilot program at Beijing ports allowing electronic customs documents for imported drugs to have equal legal effect as paper documents. Sector-wise, innovative drugs, CRO, biotech, and precious metals led gains. Analysts provided forecasts: Tianfeng Securities noted Chengdu XianDao's HAILO platform and RIPTAC pipeline progress; Southwest Securities highlighted Huiyu Pharma's 13 innovative drug projects including HY-0007 in Phase I/II trials; Pacific Securities predicted rapid growth for Hongbo Medical's commercial production after ticagrelor patent expiry; and Southwest Securities said CanSino's overseas clinical acceleration could unlock long-term pipeline value.
Read source